Acceleron related Press Releases
Acceleron Initiates Phase 1 Clinical Trial for ACE-031 to Treat Diseases Involving Muscle Loss
Acceleron Initiates Phase 1 Clinical Trial for ACE-031 to Treat Diseases Involving Muscle Loss CAMBRIDGE, Mass.--(BUSINESS WIRE)--October 20, 2008--Acceleron Pharma, Inc., a biopharmaceutical company... Read more...
Celgene Corporation and Acceleron Pharma Initiate Phase 2 Study of ACE-011 in Patients with Multiple Myeloma
Celgene Corporation and Acceleron Pharma Initiate Phase 2 Study of ACE-011 in Patients with Multiple Myeloma CAMBRIDGE, Mass.--(BUSINESS WIRE)--October 16, 2008--Celgene Corporation (NASDAQ:CELG) and... Read more...
PRESS RELEASE: Acceleron Pharma Completes $31M Series C Financing
Acceleron Pharma Completes $31M Series C Financing Top venture syndicate invests to advance expanding pipeline of products that modulate tissue growth and repair Cambridge, Mass. – October 30,... Read more...
PRESS RELEASE: Acceleron Appoints John Knopf to CEO Spot
Acceleron Appoints John Knopf to CEO Spot CAMBRIDGE, MA - September 18, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues... Read more...
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges




